Claim Discipline as Product Infrastructure

A traceable evidence capability for Gastronaut

A space-nutrition claim can outrun its evidence quietly. A simulated environment begins to stand for flight, or several papers begin to look like several experiments. Gastronaut can keep those distinctions attached to the work through ORCA’s evidence architecture. Each claim would carry its evidence tier, endpoint, exposure conditions, uncertainty, and next validation gate.

Such a record serves research planning, partner diligence, and technical assurance. It allows a claim to move forward without severing it from its origins.

What the record needs to distinguish

Gastronaut’s oxidative-stress review found that evidence labels can alter the apparent state of a field. Of 205 extracted records, 71, or 35 percent, required correction of their preliminary evidence tier after methods review. Twenty-one records first appeared to concern human spaceflight but used clinostats, rotating-wall vessels, random-positioning machines, or other simulated environments. Before methods-based classification, the apparent human-flight evidence base was about three times the verified count.

Publication count and experiment count carry different responsibilities. Twenty-one study families produced multiple records. One randomized head-down bed-rest trial of 20 men generated six papers and one registration. A mitochondrial-catalase mouse program generated seven records. The additional papers enrich what is known about each experiment; they do not add independent replications.

Tier correction and study-family clustering therefore belong where a product claim first takes shape. A customer, research partner, or investor needs to know whether evidence comes from a cell, rodent, analog participant, or crewmember. The record must also show whether papers share an experiment, whether an endpoint is a pathway marker or a health outcome, and whether the intervention was delivered in the environment where performance is claimed.

Five controls for one chain of evidence

Gastronaut can place five controls within the ORCA evidence record. Each protects a different part of the decision.

1. Where did the result occur?

Every result would identify its operating environment: terrestrial, simulated microgravity, human ground analog, non-human flight, or human flight. Radiation, gravity, atmospheric composition, mission duration, and recovery phase would remain separate fields. Any movement across environments would require an explicit transfer argument.

2. How many experiments produced the record?

Records from the same mission, trial, organism cohort, or experiment would share a study-family identifier. Evidence summaries could place publication count beside independent-study count. The Toulouse antioxidant trial would then remain one experiment with six papers, rather than becoming six replications by repetition (Kermorgant et al. 2024).

3. What level of claim has been earned?

Each statement would be assigned to the level it warrants: composition, stability, exposure, bioavailability, pathway engagement, tissue response, functional outcome, or operational value. Advancement would depend on evidence at each preceding link or a declared assumption. A measured phytochemical concentration would remain a composition result until consumption, absorption, biological response, and mission-relevant outcome were measured.

4. What qualifies the finding?

Sample size, comparator, allocation method, effect estimate, confidence interval, multiplicity control, preprint status, and missing system-cost data would travel with the claim. A reviewer could see the limits of a result without having to reconstruct the study.

5. What happens next?

Every claim would finish at a decision point: retain it as a mechanism hypothesis, repeat it in an analog, advance it to non-human flight, test it in a human-flight protocol, or retire it. The same traceable record would support scientific review and program governance.

Why ORCA needs the controls

The oxidative-stress corpus shows what is lost when these distinctions disappear. The repaired exact comparison found reported countermeasure benefit in 31 of 34 T4 simulated-microgravity records and 3 of 12 T3 human ground-analog records, an odds ratio of 31.0 with Fisher exact p = 3.5 x 10^-5 (Gastronaut 2026, GAS-OXS-CORR-2026-01). This association does not establish that evidence tier caused the difference, nor does it show that any candidate is effective in humans. Flight studies also yielded tissue-specific findings: BuOE supported retinal measures in one mouse study but did not correct muscle outcomes in another (Braun and Fajardo; Mao et al.).

An ORCA research program could hold crop chemistry, chamber conditions, harvest timing, storage, preparation, consumption, and biological sampling in one chain of custody. The claim controls would connect those observations without converting an early mechanism into an established crew-health effect. Null results would retain their place in the record. They can close a route, refine a dose, expose an environmental interaction, or redirect the endpoint.

ORCA remains a ground-stage system at approximately TRL 3 to 4, with no flight or lunar operating history. The evidence-governance capability described here is a design objective. Confidence is high that evidence-tier and study-family controls improve claim traceability, and low that those controls by themselves predict biological performance.

One record, different decisions

NASA could review a proposed study with its evidence tier, transfer assumptions, measurement plan, and stop conditions visible together. That continuity would help allocate limited flight opportunities and distinguish a technology demonstration from a human-research conclusion.

Investors could follow changes in evidence rather than a succession of broad narratives: chemistry reproduced, stability demonstrated, exposure measured, pathway engagement observed, and flight transfer tested. Each transition would reduce a named technical uncertainty without implying a financial outcome.

For Gastronaut, the record becomes an institutional memory. New evidence can revise an older claim without erasing its provenance, its limitations, or the reason it changed.

Traceability is the product. It is a claim architecture that keeps environment, experiment, endpoint, qualifier, and next decision together as ORCA matures.

References

Braun, J. L., and V. A. Fajardo. “Spaceflight Increases Sarcoplasmic Reticulum Ca2+ Leak and This Cannot Be Counteracted with BuOE Treatment.” npj Microgravity, 2024, doi:10.1038/s41526-024-00419-y.

Gastronaut. Oxidative Stress and Radiation: Evidence Synthesis. Evidence version frozen 21 Aug. 2026. Research synthesis.

Gastronaut. Gastronaut Oxidative-Stress Evidence Correction Record. GAS-OXS-CORR-2026-01, 24 Aug. 2026.

Kermorgant, M., et al. “The Effects of Antioxidant Cocktail on Ophthalmological Changes Induced by a 60-Day Head-Down Bed Rest in a Randomized Trial.” Life, vol. 14, no. 12, 2024, article 1598, doi:10.3390/life14121598.

Mao, X. W., et al. “Evidence of Spaceflight-Induced Adverse Effects on Photoreceptors and Retinal Function in the Mouse Eye.” International Journal of Molecular Sciences, 2023, doi:10.3390/ijms24087362.

Nikawa, T., et al. “Skeletal Muscle Gene Expression in Space-Flown Rats.” FASEB Journal, 2004, doi:10.1096/fj.03-0419fje.